Abstract: The application discloses an atom interferometer comprising an optical cavity and method of operation thereof. The atom interferometer includes a vacuum chamber, an optical cavity, a source for providing a cloud of atoms in the optical cavity in use, and one or more light sources. The one or more light sources are for generating, in the cavity, in use a first light beam having a first polarisation and at a first frequency for a two-photon interaction in the atoms; and a counterpropagating second light beam having a second polarisation orthogonal to the first polarisation and at a second frequency for the two-photon interaction in the atoms.

Abstract: A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.

Abstract: The present invention relates to a genetic probe comprising: a nanoparticle; an oligonucleotide probe anchored to the surface of the nanoparticle, comprising an oligonucleotide backbone with a tag incorporated therein via a linker group; and a reference probe anchored to the surface of the nanoparticle, wherein the reference probe comprises a marker; wherein either (a) the tag is an organic fluorescent tag and the marker is a transition metal-based fluorescent marker; or (b) the tag is a redox-active tag and the marker is a transition metal-based redox-active marker. The invention also relates to a composition or kit containing a probe of the invention.

Abstract: An apparatus for generating vertically separated atom clouds. The apparatus comprises an optical system comprising an arrangement of lenses and optics. The optical system is configured to trap and cool atoms to form a cold atom cloud; select the hyperfine level of the atoms; trap atoms of the cold atom cloud in a standing wave optical lattice; and vertically split the cold atom cloud into a high cold atom cloud and a low cold atom cloud. The splitting comprises splitting the cold atom cloud into two clouds by launching atoms of the cold atom cloud in opposite directions to form a high cold atom cloud and a low cold atom cloud, and catching the low cold atom cloud up to reach the same velocity as the high cold atom cloud.

Abstract: A single arm laser system comprising a first in-phase quadrature modulator, IQM. The first IQM is configured to receive a single frequency fibred laser beam from a frequency locked laser seed, generate a first single side-band frequency based on a carrier frequency of the single frequency fibred laser beam and suppress the carrier frequency, and output a first fibre laser beam having a single side-band suppressed carrier frequency. The single arm laser system also comprises a second IQM in line with the first IQM. The second IQM is configured to receive the first fibre laser beam from the first IQM, generate a second single side-band frequency based on the first single side-band frequency and maintain the first single side-band frequency as the carrier frequency, and output a second fibre laser beam having the first and second single side band frequencies.

Abstract: An apparatus for generating vertically separated atom clouds. The apparatus comprises an optical system comprising an arrangement of lenses and optics. The optical system is configured to trap and cool atoms to form a cold atom cloud; select the hyperfine level of the atoms; trap atoms of the cold atom cloud in a standing wave optical lattice; and vertically split the cold atom cloud into a high cold atom cloud and a low cold atom cloud. The splitting comprises splitting the cold atom cloud into two clouds by launching atoms of the cold atom cloud in opposite directions to form a high cold atom cloud and a low cold atom cloud, and catching the low cold atom cloud up to reach the same velocity as the high cold atom cloud.

Abstract: A single arm laser system comprising a first in-phase quadrature modulator, IQM. The first IQM is configured to receive a single frequency fibred laser beam from a frequency locked laser seed, generate a first single side-band frequency based on a carrier frequency of the single frequency fibred laser beam and suppress the carrier frequency, and output a first fibre laser beam having a single side-band suppressed carrier frequency. The single arm laser system also comprises a second IQM in line with the first IQM. The second IQM is configured to receive the first fibre laser beam from the first IQM, generate a second single side-band frequency based on the first single side-band frequency and maintain the first single side-band frequency as the carrier frequency, and output a second fibre laser beam having the first and second single side band frequencies.

Abstract: A method of processing NdFeB magnetic powder comprises: providing a source of hydrogenated NdFeB powder (101, 102, 103); feeding said powder into an inlet of a cyclone separator (104); separating the powder into an overflow enriched in Nd-rich grain boundary phase and an underflow enriched in NdxFeyBHz matrix phase particles (106); optionally feeding the underflow back into the inlet of the cyclone separator whereby to further enrich the underflow in the NdxFeyBHz matrix phase particles (108a); and collecting the underflow (108).

Abstract: The invention relates to a genetic probe, wherein the genetic probe comprises: an oligonucleotide, or an oligonucleotide analogue, with a Raman-active moiety incorporated therein, wherein the Raman-active moiety is incorporated into a base of the oligonucleotide or oligonucleotide thereof; and associated methods, uses, kits and compositions for determining a single point variant nucleotide in a target nucleic acid.

Abstract: The present disclosure relates to the treatment of neurological conditions, by inhibiting Chk2 kinase. Particular neurological conditions may be associated with neuronal damage/dysfunction or neurological degeneration, which may result from, physical trauma, chemical means, infection, inflammation, hypoxia and/or interruption in blood supply, or be due to a neurodegenerative disorder and/or autoimmune disease. The Chk2 inhibitor may be a small molecule, protein, peptide or nucleic acid. Exemplary small molecule Chk2 inhibitors include PV1019, AZD7762, CCT241533, BML-277 or prexasertib.

Abstract: A stimuli-responsive surface (3) comprising a substrate (20) on which is located a switchable molecule (2) which has a functional moiety (22) associated therewith, wherein the switchable molecule (2) has a first equilibrium state (2A) in which access to the functional moiety (22) is inhibited and a second stimulated state (2B), in which access to the functional moiety (22) is permitted.

Abstract: Provided herein are methods to predict pain sensitivity and pain intensity to prolonged pain in a subject. Electroencephalograms are recorded in a pain-free state or, alternatively, in a pain-free state and after applying a prolonged pain stimulus in a prolonged pain state. Pain-free and prolonged pain peak alpha frequencies or ?PAF are measured. These values correlate negatively with the likelihood of increased pain sensitivity and increased pain intensity. Also provided is a method for predicting a likelihood of chronic pain in a subject after a medical procedure and designing a plan to treat the chronic pain.

Abstract: A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.

Abstract: Compositions that include anti-cancer, anti-tumor, and anti-microbial infection peptides are provided. In some embodiments, the compositions include 1-10 or more synthetic peptides that are between 8 and 50 amino acids long and include an amino acid sequence as disclosed herein.

Abstract: A method for controlling a wind turbine system connected to a power grid. The method comprises generating a wind turbine control signal based on a power control reference for controlling a power output of a wind turbine; monitoring an electrical frequency of the power grid; in response to detecting a change in the frequency in the power grid, activating a fast frequency support method comprising the steps of; adjusting the power control reference to cause an overproduction of power by the wind turbine; the overproduction of power causing a transfer of inertial kinetic energy from the wind turbine to electrical power; wherein the power control reference is determined by applying an adaptive gain function to a measurement of a difference in grid frequency from a nominal level.

Abstract: Provided are compositions that include one or more synthetic target peptides, wherein each synthetic target peptide is about or at least 8-50 amino acids long; and has an amino acid sequence as set forth in Table 2 and/or Table 3. Also provided are in vitro populations of dendritic cells that include the disclosed compositions, in vitro population of CD8+ T cells capable of being activated upon being brought into contact with the disclosed populations of dendritic cells, antibodies or antibody-like molecules that specifically binds to a complex of an MHC class I molecule and a peptide having an amino acid sequence as set forth in Table 2 and/or Table 3, methods for treating and/or preventing cancers by administering a therapeutically effective dose of a composition that includes at least one target peptide having an amino acid sequence as set forth in Table 2 and/or Table 3.

Abstract: The present invention relates to a drug delivery system and methods of using the delivery system, particularly a delivery system for transporting pharmaceutically active agents across, for example, the skin, the surface of the eye or mucosal membranes. The drug delivery system comprises a pharmaceutically effective moiety and a polyamine or amine moiety, wherein the polyamine or amine moiety does not comprise two or more contiguous basic amino acid residues. The drug delivery system may be provided for use as a medicament, or for use in the treatment of a disease or condition selected from eye disease, burns, infection, and trauma. The invention also provides a method comprising administering a pharmaceutically effective amount of the drug delivery system of the invention to a patient in need thereof.

Abstract: A process is provided for the production of rare earth magnets comprising the steps of exposing a rare earth alloy to hydrogen gas at an elevated temperature so as to effect hydrogenation and disproportionation of the alloy, mechanically processing the disproportionated alloy, and degassing the processed alloy so as to effect hydrogen desorption and recombination of the alloy. The process of the invention finds use in the production and shaping of rare earth magnets, and may be particularly applicable to the production of thin magnetic sheets.

Abstract: Provided is a method that utilises linear dichroism (LD) to identify the presence of a target molecule (L) in a sample. The method comprises providing an alignable scaffold (20), preferably biomolecular fibre M13, comprising a first binding region and having a high aspect ratio of greater than 5:1, providing a substrate (e.g. a substantially spherical non-alignable moiety (12)) comprising a second binding region which binds the first binding region in the absence of the target molecule in such a way that the LD signal of the alignable scaffold is reduced or minimised relative to the unbound and aligned scaffold, wherein one of the first and second binding regions is a receptor capable of binding the target molecule, exposing the substrate-bound scaffold to the sample such that binding of the target molecule, if present, to the receptor releases the scaffold from the substrate, and measuring the LD signal of the scaffold before and after exposure to the sample.

Abstract: A method of treating a polymer surface using conventional plasma nitriding, and a nitrided polymer surface obtained thereby. The method comprises introducing nitrogen into the polymer surface using conventional plasma nitriding, and optionally functionalizing the nitrided polymer surface with a molecule, such as an antimicrobial moiety, which is capable of forming a covalent bond with the nitrogen atoms within the polymer surface.